The purpose of this work is to provide comparison data for muscle strength and measures of activity and participation stratified by GMFCS level, age, and cerebral palsy (CP) type. Clinicians can use the data to determine treatment goals based on the patients' matched peer group. Methods used were data were collected on 377 individuals with hemiplegia and diplegia, GMFCS levels I-III, ages eight to18 years. Lower extremity muscle strength, Gillette gait index (GGI), one-minute walk test (1MWT), and timed up-and-go (TUG) were collected. Results showed that strength differed among GMFCS levels and age for both CP types. The GGI and 1 MWT discriminated among GMFCS levels within each CP type. The TUG discriminated between GMFCS levels I and III and levels II and III for the diplegic group. We conclude that differences in strength and measures of activity and participation were found across GMFCS levels and CP type. The reported stratified data can serve as an important clinical tool in determining realistic treatment goals and clinical outcomes.
I. INTRODUCTION
Comparison of function in children with cerebral palsy (CP) based on severity, age, and distribution of limb involvement is fundamental when determining appropriate clinical care and conducting clinical research. Standardized outcome tools are routinely used to quantify body functions and structures, activities and participation for individuals with CP. [1] [2] [3] [4] [5] Hassani et al Investigators previously reported descriptive characteristics of several outcome tools in ambulatory children with CP stratified by severity level. 6-8. Oeffinger et al. 6, 9 found a direct relationship between gross motor function classification system (GMFCS) level 2 and the pediatric outcomes data collection instrument (PODCI), 4 pediatric functional independence measure (WeeFIM), 3 Gillette functional assessment questionnaire (FAQ), 1 gross motor function measure (GMFM), 10 energy cost during walking (O 2 cost), and temporal-spatial gait parameters. The study showed a direct relationship between increasing severity and decreasing scores on outcome tools. The results provided descriptive data, by severity level, that clinicians can use for comparison with individual children with CP.
Age has been found to be associated with gross motor function of children with CP. 11 Differential rates and limits of gross motor development were found among children of different GMFCS levels. 12 Wright et al. 13 described patterns of gross motor development of children with CP. The GMFCS was used as a predictive measure, longitudinally tracking the rates and limits of motor function (GMFM scores) of children with similar age and severity.
In addition to severity and age, consideration of the type of CP has been shown to be important when assessing children using outcome tools. Damiano et al. 14 reported descriptive characteristics of children with CP and compared those with hemiplegia to those with diplegia by GMFCS level. Results showed that children with hemiplegia presented differently from those with diplegia on the PODCI, WeeFIM, GMFM, FAQ, O 2 cost , and gait metrics. Children with hemiplegia had worse upper extremity function but better gait and lower extremity function than children with diplegia.
While previous studies have focused on differences by CP type, severity level, or age, few have used all three stratifications. Strength is important in this population. Children with CP are weaker than their peers, 15 which could lead to decreased function on measures of activity and participation. Strength assessments are used frequently in clinical settings to determine if specific muscle weakness exists. Limited comparison data for overall lower extremity strength and individual muscle strength for ambulatory children with CP by CP type, GMFCS levels, and age are available in the literature. 15, 16 Assessments used to test endurance, balance, and gait deviations in individuals with CP include measures of activity and participation such as the one-minute walk test (1MWT), timed up-and-go (TUG), and the Gillette gait index (GGI). The 1MWT is a valid measure of functional mobility and endurance in children with CP. 17 TUG measures basic mobility, dynamic balance, and function, 18 and may be used for any population with impaired balance. [19] [20] [21] [22] [23] TUG may serve as an accurate tool in assessing the efficiency of transitions and gait in children with CP. The GGI is a measure of gait deviation that incorporates 16 kinematic and temporal-spatial parameters. 1, 24 The GGI can distinguish between types of CP (hemiplegia and diplegia) as well as between involved and uninvolved limbs of individuals with hemiplegic CP. to clinicians that allow for comparison of individuals with CP to others with similar severity levels, age, and CP type, leading to better clinical decision making, posttreatment follow-up, and experimental designs. This paper builds on previous work by the Functional Assessment Research Group that evaluated multiple outcome tools stratified by GMFCS level and CP type in ambulatory children with CP 6, 8, 9, 14, 27, 28 and includes new measures of TUG, 1MWT, GGI, and lower extremity strength.
II. METHODS

A. Participants
This study was part of a four-year prospective multicenter study. Participants were a convenience sample of eligible patients from seven pediatric orthopedic hospitals. Institutional Review Board approval was obtained at each site and consent and Health Insurance Portability and Accountability Act forms were completed.
Inclusion criteria were: patients with a diagnosis of spastic CP, in GMFCS levels I-III, ages 8 to 18 years, and who were able to complete an instrumented gait analysis with or without assistive devices. Patients were excluded if they had lower extremity orthopedic surgery within the last year, botulinum toxin A injections in the past four months, or a currently implanted and operating baclofen pump. A total of 748 patients were assessed: 273 did not meet inclusion criteria; 80 declined participation. Demographic characteristics of individuals who did not participate were not different from those who did. Data from 18 participants were excluded for inconsistent or missing data, resulting in 377 in the final analysis.
B. Data Management
Before study initiation, all coordinators attended a mandatory two-day training session to review and standardize administration of the outcome tools and data collection processes. All participant data were entered directly into a custom database designed for study management and data collection. Encoded data from each site were compiled for analysis. Data quality and consistency was ensured by the project manager and site coordinators.
C. Assessment Tools
Each participant completed an assessment that included GMFCS, height, weight, and pubertal stage measured by self-report of the Tanner scale. Patient history was collected that included gestational age, race, limb involvement, age at walking onset, additional diagnoses, and previous surgeries. Each participant completed an instrumented gait analysis, 1MWT, and TUG as measures of activity and participation. Lower extremity strength was also collected. 16 To compare current findings with our previous work, 6, 8, 9, 27 PODCI, GMFM, gait temporal-spatial parameters, and O 2 cost were also collected.
During the 1MWT, participants were instructed to walk using their typical walking aids, orthoses, and shoes at their fastest pace possible, without running, for 1 min. Total distance in meters walked were recorded. For the TUG, the length of time (seconds) was recorded for rising from the sitting position in a chair, walk 3 m, touch the wall, turn around, walk back, and sit down while using customary walking aids, orthoses, and shoes.
Participants were evaluated using instrumented gait analysis. All subjects walked barefoot at self-selected walking speed. GGI was calculated for three representative trials and averaged to obtain the GGI score. For children with diplegia, the GGI data from the left and right limbs were averaged to give the total GGI score. For those with hemiplegia, total GGI score and individual GGI scores of involved and uninvolved sides were calculated.
Lower extremity muscle strength of the hip flexors, extensors, abductors and adductors, knee flexors and extensors, and ankle plantar flexors and dorsiflexors were assessed using a standardized protocol with a handheld dynamometer (HHD) (JTECH PowerTrack II Commander, Salt Lake City, Utah). All examiners received training on the standardized protocol, and reliability testing was completed. Strength scores for each individual muscle was the maximum value of three trials. Two aggregate strength scores were collected. Total strength score was calculated by averaging the individual strength scores for all muscles bilaterally. Total extensor strength was the sum of hip and knee extensors, and ankle plantar flexors bilaterally. All strength scores were normalized to body weight.
D. Statistical Analysis
Descriptive statistics were calculated for all interval variables and were analyzed by GMFCS level, type of CP (hemiplegia or diplegia), and age group. Participants with hemiplegia and diplegia were analyzed separately for all analyses. Three age groups were created: prepubescent (age group 1: 8-<11 years), pubescent (age group 2: 11-<14 years), and postpubescent (age group 3: 14-19 years). Paired t-tests were used to compare differences between CP types. ANOVAs were used to analyze differences among GMFCS levels and age groups. Post hoc tests were performed to examine significant main effects. Due to the large number of parallel tests, a p < 0.01 was set a priori as the significance level for all statistical tests.
III. RESULTS
Participant demographics are reported for the diplegic and the hemiplegic groups (Table 1) . Of the 377 subjects, 273 (72%) were diplegic and 104 (28%) were hemiplegic. Within the diplegic group, 67 (25%) were GMFCS level I, 130 (48%) were GMFCS level II, and 76 (28%) were GMFCS level III. Also, 72 (26%) were in age group 1, 103 (38%) in age group 2, and 98 (36%) in age group 3. One hundred and sixty (59%) previously had musculoskeletal surgery. Two hundred and fourteen (79%) were Caucasian, 19 (7%) were African-American, 21 (8%) were Hispanic/Latino, and 16 (6%) were considered as other. Within the hemiplegic group, 81 (78%) were GMFCS level I and 23 (22%) were GMFCS level II. Thirty-six (35%) were in age group I, 30 (29%) in age group II, and 38 (36%) in age group III. Sixty-six (64%) previously had musculoskeletal surgery and 38 (36%) did not. Eighty-three (81%) were Caucasian, 7 (7%) were African-American, 7 (7%) were Hispanic/Latino, and 6 (5%) were considered as other.
Data were analyzed to assess site bias for all study measures. No differences in data collected across sites were found for any measures except for strength. The PODCI, GMFM, gait temporal-spatial, and O 2 cost data were nearly identical to those previously published by Oeffinger et al. A. Descriptive Statistics
Diplegia
When comparing GMFCS levels for the diplegic group, differences were observed across all levels for 1MWT, TUG, and GGI scores (Table 2 ). Specifically, 1MWT (Table 3) , the prepubescent group (age group 1) was the strongest, based on normalized strength. They were stronger than the pubescent group (age group 2) for hip adductors, knee extensors, knee flexors, total extensors, and total strength, and stronger than the postpubesent (age group 3) for all muscle groups except ankle dorsiflexors and hip extensors. There were no differences in strength identified between the pubescent (age group 2) and postpubescent groups (age group 3). No differences in the scores on the activity and participation measures were observed among age groups. 
Hemiplegia
For the hemiplegic group (Table 4) , distances walked in 1MWT decreased between levels I and II and total GGI scores increased. Differences in GGI scores were seen between GMFCS levels I and II for both the involved and uninvolved sides. Strength decreased with increasing severity for the involved sides' hip abductors, knee extensors (30 deg), knee flexors, and total extensors. For the uninvolved side, GMFCS level II were weaker than level I for hip abductors, hip extensors, knee extensors (30 deg), and total extensors. No differences in strength or outcome measure scores were identified when age groups were compared. 
Diplegia versus Hemiplegia
Differences were seen between the subset of the diplegic group (GMFCS levels I and II) and hemiplegic groups for the 1MWT (diplegia: 68.6 ± 21.7 m, hemiplegia: 85.0 ± 18.5 m) and TUG (diplegia: 13.1 ± 13.1 s, hemiplegia: 6.9 ± 1.7 s), with the hemiplegic group having greater function. For total GGI score at GMFCS level II (diplegia: 244.7 ± 125.7, hemiplegia: 461.8 ± 419.1), diplegics had less gait deviation than hemiplegics (involved side). Strength scores were similar between those with hemiplegia and those with diplegia. Differences were seen in normalized hip abductors (diplegia: 2.0 ± .9, hemiplegia: 2.3 ± .9) and hip flexors (diplegia: 2.3 ± 1.1, hemiplegia: 2.9 ± 1.2), as well as normalized plantarflexor strength at GMFCS level I (diplegia: 3.3 ± 2.4, hemiplegia: 2.3 ± 1.7).
IV. DISCUSSION
The findings from this study are part of a broader multicenter study to identify factors that help explain the variance in measures of activity and participation accounting for CP type, severity level, and age. The descriptive statistics reported are representative of a group of ambulatory children with CP ranging from eight to 18 years of age. The 1MWT is quick and easy, and requires minimal space to measure functional mobility and endurance. Our results are consistent with previous findings 17 that the 1MWT can differentiate among severity levels and CP type. However, previous researchers did not stratify by CP type, and assessed only 34 participants among the four GMFCS levels. 17 Based on our findings, clinicians can quickly assess and compare their patients to the mean distance of the 1MWT based on severity level and CP type.
While the TUG is a valid tool to assess balance in children with CP, 18 it only detected differences between GMFCS levels I and III and levels II and III in the diplegic group. The TUG did not differentiate by severity level for the hemiplegic group. These findings are consistent with Gan et al., 29 who reported that the TUG and Berg balance scale (BBS) were unable to distinguish between GMFCS levels I and II in children with CP. However, in their study, the sample of 30 children was not stratified by CP type, and included children with diplegia, hemiplegia, quadriplegia, ataxia, and athetosis. Although Williams et al. 18 reported that the TUG can differentiate among GMFCS levels when stratified by CP type, only a small sample size was tested. Based on our findings, a more discriminative or more physically challenging tool is necessary to measure differences in functional mobility in children with GMFCS levels I and II.
The GGI was able to differentiate among severity levels for children with diplegia, as well as between GMFCS levels, and the uninvolved and involved sides for children with hemiplegia. While these findings were consistent with Schutte et al., 26 the GGI only differentiated between individuals with hemiplegia and diplegia at GMFCS level II, but not for the less involved GMFCS level I group. Overall, the GGI is an accurate and reliable tool to provide a global assessment of a patient's gait deviations compared to peers. Surprisingly, activity and participation scores in this study did not differ by age. Previous studies reported that age is associated with gross motor function, activity, and participation when stratified by GMFCS level. 13, 30 The GMFM has been reported to differentiate among age groups, showing that function deteriorates as a child with CP gets older primarily in levels III, IV, and V. 30 Strength measures differed among age groups for both CP types. Specifically, the prepubescent group exhibited higher normalized strength values for several muscle groups when compared to the pubescent and postpubescent age groups. No previous studies have stratified normalized strength values by age group, GMFCS level, and CP type. Muscle strength has been directly correlated with motor function in children with CP. [31] [32] [33] [34] Based on these findings, strength training may be indicated for children as they progress into puberty and adulthood.
In addition to age, muscle strength varied by GMFCS level for the hemiplegic and diplegic groups. Participants exhibited greater muscle weakness as their GMFCS level increased. Wiley et al. 16 reported lower extremity muscle weakness in ambulatory children with hemiplegia and diplegia compared to age-matched peers using the HHD, but did not stratify by GMFCS levels. To our knowledge, no study to date has stratified lower extremity muscle strength by both GMFCS level and CP type. The data reported from this study could assist therapists in baseline assessment and treatment goals. For example, if a child with diplegic CP (GMFCS level II) who ambulates 40 m for the 1MWT walks a significantly shorter distance than their peers (70 ± 17.3 m). Based on this comparison, a physical therapist would focus on endurance and speed training to help the child reach their full potential.
A. Limitations
A potential limitation of the study was that there may have been differences between evaluators for strength measurements despite standardization of the protocol and training of all assessors. Some difference may be due to the individual evaluator strength. Despite the significant differences in magnitude of the measurements among examiners, the study trends were the same for all evaluators. Isokinetic machines could provide more accurate, reliable readings, but can be expensive and not always easily accessible or practical in a clinical setting. While the sample size was large, when the data were stratified by both CP type and GMFCS levels, the findings may be limited by the small sample size in GMFCS level II for the hemiplegic group.
V. CONCLUSION
Differences in strength and measure of activity and participation were found across GMFCS levels and CP type. For the diplegic group, strength data and the activity and participation measures of 1MWT, TUG, and GGI differed by severity level. For the hemiplegic group, the 1MWT and GGI differed by GMFCS level. The 1MWT, a simple, quick measure of endurance, proved to be discriminative among GMFCS levels and between CP types. The GGI was discriminative among GMFCS levels within each CP type.
This study enhanced our previous work by assessing strength and additional outcome tools to measure activity and participation across GMFCS levels, age, and CP type. Comparison data for lower extremity strength, 1MWT, TUG, and GGI by GMFCS level and CP type is provided. By comparing a child's score to the reported data stratified by severity, age, and CP type, clinicians can use the data to determine treatment goals and assess long-term follow-up based on the patient's matched peer group. Future work from this study includes analyzing relationships among the tools. Also, the longitudinal component of the study will allow us to measure changes in these tools over time in ambulatory children with CP.
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